BRPI0816679A2 - Derivados de ftalazinona. - Google Patents

Derivados de ftalazinona.

Info

Publication number: BRPI0816679A2
Authority: BR; Brazil
Prior art keywords: ftaazinone; derivatives; ftaazinone derivatives
Prior art date: 2007-09-14

Application number

Other languages

English (en)

Inventor

Muhamed Hashim Javaid

Keith Allan Menear

Niall Morrison Barr Martin

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-14

Filing date

2008-09-12

Publication date

2015-03-17

2008-09-12 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2015-03-17 Publication of BRPI0816679A2 publication Critical patent/BRPI0816679A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Transplantation (AREA)
Psychology (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Virology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

BRPI0816679 2007-09-14 2008-09-12 Derivados de ftalazinona. BRPI0816679A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US97238407P	2007-09-14	2007-09-14
US3264208P	2008-02-29	2008-02-29
PCT/GB2008/003080 WO2009034326A1 (en)	2007-09-14	2008-09-12	Phthalazinone derivatives

Publications (1)

Publication Number	Publication Date
BRPI0816679A2 true BRPI0816679A2 (pt)	2015-03-17

Family

ID=40091299

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0816679 BRPI0816679A2 (pt)	2007-09-14	2008-09-12	Derivados de ftalazinona.

Country Status (11)

Country	Link
US (1)	US7981890B2 (pt)
EP (1)	EP2188278A1 (pt)
JP (1)	JP2010539149A (pt)
KR (1)	KR20100059950A (pt)
CN (1)	CN101809017A (pt)
AU (1)	AU2008299721A1 (pt)
BR (1)	BRPI0816679A2 (pt)
CA (1)	CA2699038A1 (pt)
MX (1)	MX2010002749A (pt)
RU (1)	RU2010108008A (pt)
WO (1)	WO2009034326A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0521373D0 (en) *	2005-10-20	2005-11-30	Kudos Pharm Ltd	Pthalazinone derivatives
MX347085B (es) *	2006-12-28	2017-04-06	Abbott Laboratories *	Inhibidores de la poli (adp-ribosa) polimerasa.
US8466150B2 (en)	2006-12-28	2013-06-18	Abbott Laboratories	Inhibitors of poly(ADP-ribose)polymerase
US20080280910A1 (en) *	2007-03-22	2008-11-13	Keith Allan Menear	Phthalazinone derivatives
TW200900396A (en) *	2007-04-10	2009-01-01	Kudos Pharm Ltd	Phthalazinone derivatives
AR070221A1 (es) *	2008-01-23	2010-03-25	Astrazeneca Ab	Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
TWI577693B (zh)	2011-05-31	2017-04-11	江蘇康緣藥業股份有限公司	聚（ａｄｐ-核糖）聚合酶之三環抑制劑
CA3129516A1 (en) *	2018-02-28	2019-09-06	The Trustees Of The University Of Pennsylvania	Low affinity poly(ad-ribose) polymerase 1 dependent cytotoxic agents

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB721286A (en)	1951-02-16	1955-01-05	Smith Kline & French Internat	Improvements in or relating to the preparation of tetrahydroisoquinolone derivatives
DE2143745A1 (de)	1971-09-01	1973-03-08	Hoechst Ag	3,4-dihydro-2h-isochinolin-1-thione und verfahren zu ihrer herstellung
US3813384A (en)	1972-01-17	1974-05-28	Asta Werke Ag Chem Fab	Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
FR2262513A1 (en)	1974-03-01	1975-09-26	Delalande Sa	3,4,5-Triphenyl-delta-1,2,4-oxadiazolines - with bronchodilator, anti-cholinergic, hypertensive, analgesic and sedative activity
JPS54156526A (en)	1978-05-31	1979-12-10	Asahi Chemical Ind	Dry picture forming material
US4283539A (en)	1979-12-18	1981-08-11	Pfizer Inc.	Isoquinoline acetic acids
JPS58164577A (ja)	1982-03-24	1983-09-29	Taiho Yakuhin Kogyo Kk	４―ベンジル―１―（２ｈ）イソキノロン誘導体
US4665181A (en)	1984-05-17	1987-05-12	Pennwalt Corporation	Anti-inflammatory phthalazinones
US5041653A (en)	1985-05-03	1991-08-20	Sri International	Substituted benzamide radiosensitizers
US5215738A (en)	1985-05-03	1993-06-01	Sri International	Benzamide and nicotinamide radiosensitizers
US5032617A (en)	1985-05-03	1991-07-16	Sri International	Substituted benzamide radiosensitizers
DE3677322D1 (de)	1985-11-11	1991-03-07	Asta Pharma Ag	4-benzyl-1-(2h)-phthalazinon-derivate.
GB8610018D0 (en)	1986-04-24	1986-05-29	Fujisawa Pharmaceutical Co	Phthalazine derivatives
DE3640641A1 (de)	1986-11-28	1988-07-14	Thomae Gmbh Dr K	Neue heteroaromatische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3813531A1 (de)	1987-05-02	1988-11-10	Asta Pharma Ag	Neue 2-aminoalkyl-4-benzyl-1-(2h)-phthalazinon-derivate
JP2786896B2 (ja)	1988-08-19	1998-08-13	ワーナー―ランバート・コンパニー	置換されたジヒドロイソキノリノンおよび関連化合物
ES2075082T3 (es)	1989-03-28	1995-10-01	Nisshin Flour Milling Co	Derivados de isoquinolina para el tratamiento del glaucoma o hipertension ocular.
DD287032A5 (de)	1989-07-28	1991-02-14	Karl-Marx-Universitaet Leipzig,De	Verfahren zur herstellung von 3-carbamoyl-4-aryl-1,2-di-hydro-isochinolin-1h-onen
GB9011833D0 (en)	1990-05-25	1990-07-18	Collins Mary K L	Inhibition of viral infection
EP0502575A1 (en)	1991-03-06	1992-09-09	Merck & Co. Inc.	Substituted 1-(2H)-isoquinolinones
ZA93282B (en)	1992-01-17	1994-07-15	Syntex Inc	Substituted 1-isoquinolone derivatives
CZ199593A3 (en)	1992-10-02	1994-04-13	Asta Medica Ag	Phthalazinone derivatives exhibiting anti-arrhythmic and analgesic activity and eliminating resistance to a plurality of medicaments (mdr)
WO1994010151A1 (en)	1992-11-02	1994-05-11	Merck & Co., Inc.	Substituted phthalazinones as nerotensin antagonists
EP0634404A1 (en)	1993-07-13	1995-01-18	Rhone Poulenc Agriculture Ltd.	Phtalazin derivatives and their use as pesticides
US5587384A (en)	1994-02-04	1996-12-24	The Johns Hopkins University	Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US5648355A (en)	1994-02-09	1997-07-15	Kos Pharmaceutical, Inc.	Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
GB9404485D0 (en)	1994-03-09	1994-04-20	Cancer Res Campaign Tech	Benzamide analogues
DE69521002T3 (de)	1994-08-12	2010-02-25	The University Of Utah Research Foundation, Salt Lake City	Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens
EP0699754B2 (en)	1994-08-12	2009-08-12	The University of Utah Research Foundation	Method for diagnosing a predisposition for breast and ovarian cancer
US5589483A (en)	1994-12-21	1996-12-31	Geron Corporation	Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
US5834466A (en)	1994-12-22	1998-11-10	The Regents Of The University Of California	Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
IL120264A0 (en)	1996-02-29	1997-06-10	Pfizer	Method of reducing tissue damage associated with non-cardiac ischemia
CA2205757C (en)	1996-05-30	2006-01-24	F. Hoffmann-La Roche Ag	Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii)
US5888529A (en)	1997-03-28	1999-03-30	The Regents Of The University Of California	Ileus treatment method
EP1009404A4 (en)	1997-05-13	2009-07-01	Octamer Inc	PROCESS FOR TREATING INFLAMMATION OR INFLAMMATORY DISEASES USING POLY-ADP RIBOSE POLYMERASE INHIBITORS
WO1999008680A1 (en)	1997-08-15	1999-02-25	The Johns Hopkins University	Method of using selective parp inhibitors to prevent or treat neurotoxicity
US6635642B1 (en)	1997-09-03	2003-10-21	Guilford Pharmaceuticals Inc.	PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6197785B1 (en)	1997-09-03	2001-03-06	Guilford Pharmaceuticals Inc.	Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6291425B1 (en)	1999-09-01	2001-09-18	Guilford Pharmaceuticals Inc.	Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US6514983B1 (en)	1997-09-03	2003-02-04	Guilford Pharmaceuticals Inc.	Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US20020022636A1 (en)	1997-09-03	2002-02-21	Jia-He Li	Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6426415B1 (en)	1997-09-03	2002-07-30	Guilford Pharmaceuticals Inc.	Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
JP2001522884A (ja)	1997-11-14	2001-11-20	イーライ・リリー・アンド・カンパニー	アルツハイマー病の処置方法
EP1066039A4 (en)	1998-03-02	2003-02-26	Cocensys Inc	SUBSTITUTED QUINAZOLINE AND THEIR ANALOGS AND USES
FR2776291B1 (fr)	1998-03-18	2000-06-16	Pf Medicament	Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament
ITMI981671A1 (it)	1998-07-21	2000-01-21	Zambon Spa	Derivati ftalazinici inibitori della fosfodisterasi 4
EP1140936B1 (en)	1999-01-11	2004-03-17	Agouron Pharmaceuticals, Inc.	Tricyclic inhibitors of poly(adp-ribose) polymerases
KR20010101675A (ko)	1999-01-26	2001-11-14	우에노 도시오	2ｈ-프탈라진-1-온 유도체 및 그 유도체를 유효 성분으로하는 약제
DE19921567A1 (de)	1999-05-11	2000-11-16	Basf Ag	Verwendung von Phthalazine-Derivaten
US6465448B1 (en)	1999-08-13	2002-10-15	Case Western Reserve University	Methoxyamine potentiation of temozolomide anti-cancer activity
ECSP003637A (es)	1999-08-31	2002-03-25	Agouron Pharma	Inhibidores triciclicos de poli (adp-ribosa) polimerasas
AU7314200A (en)	1999-09-17	2001-04-24	Yamanouchi Pharmaceutical Co., Ltd.	Benzimidazole derivatives
KR20010087401A (ko)	1999-09-28	2001-09-15	스타르크, 카르크	아제피노인돌 유도체, 그의 제법 및 용도
US6476048B1 (en)	1999-12-07	2002-11-05	Inotek Pharamaceuticals Corporation	Substituted phenanthridinones and methods of use thereof
ES2290115T3 (es)	2000-02-01	2008-02-16	ABBOTT GMBH & CO. KG	Compuestos heterociclicos y su aplicacion como inhibidores de parp.
AU2001248748A1 (en)	2000-04-18	2001-10-30	Sumitomo Pharmaceuticals Company, Limited	Substituted piperazine compounds
US7122679B2 (en)	2000-05-09	2006-10-17	Cephalon, Inc.	Multicyclic compounds and the use thereof
DE10022925A1 (de)	2000-05-11	2001-11-15	Basf Ag	Substituierte Indole als PARP-Inhibitoren
WO2001087845A2 (en)	2000-05-15	2001-11-22	Fujisawa Pharmaceutical Co., Ltd.	N-containing heterocyclic compounds and their use as 5-ht antagonists
US6723733B2 (en)	2000-05-19	2004-04-20	Guilford Pharmaceuticals, Inc.	Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses
HU228960B1 (hu)	2000-10-30	2013-07-29	Kudos Pharm Ltd	Ftalazinon-származékok
US7151102B2 (en)	2000-10-30	2006-12-19	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
AU2002220241A1 (en)	2000-12-01	2002-06-11	Iconix Pharmaceuticals, Inc.	Parb inhibitors
WO2002068407A1 (en)	2001-02-28	2002-09-06	Yamanouchi Pharmaceutical Co., Ltd.	Benzimidazole compound
WO2002090334A1 (en)	2001-05-08	2002-11-14	Kudos Pharmaceuticals Limited	Isoquinolinone derivatives as parp inhibitors
US20040176361A1 (en)	2001-05-23	2004-09-09	Masakazu Fujio	Fused heterocyclic compound and medicinal use thereof
WO2003007959A1 (en)	2001-07-16	2003-01-30	Fujisawa Pharmaceutical Co., Ltd.	Quinoxaline derivatives which have parp inhibitory action
AU2002358650A1 (en)	2001-12-14	2003-06-30	Altana Pharma Ag	Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
AUPR975601A0 (en)	2001-12-24	2002-01-31	Fujisawa Pharmaceutical Co., Ltd.	Quinazolinone derivatives
WO2003057145A2 (en)	2001-12-31	2003-07-17	Guilford Pharmaceuticals Inc.	SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES
AUPS019702A0 (en)	2002-01-29	2002-02-21	Fujisawa Pharmaceutical Co., Ltd.	Condensed heterocyclic compounds
KR100663147B1 (ko)	2002-02-19	2007-02-28	오노 야꾸힝 고교 가부시키가이샤	축합 피리다진 유도체 화합물 및 이를 유효 성분으로서함유하는 약제
JP4561698B2 (ja) *	2002-02-19	2010-10-13	小野薬品工業株式会社	縮合ピリダジン誘導体化合物およびその化合物を有効成分として含有する薬剤
MXPA04007809A (es)	2002-02-25	2004-10-15	Kudos Pharm Ltd	Piranonas utiles como inhibidores de ataxia-telangetaxia mutada.
DE60335359D1 (de)	2002-04-30	2011-01-27	Kudos Pharm Ltd	Phthalazinonderivate
US7449464B2 (en)	2003-03-12	2008-11-11	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
SG150548A1 (en)	2003-12-01	2009-03-30	Kudos Pharm Ltd	Dna damage repair inhibitors for treatment of cancer
WO2006003147A1 (en) *	2004-06-30	2006-01-12	Janssen Pharmaceutica N.V.	Phthalazine derivatives as parp inhibitors
KR20070057859A (ko) *	2004-08-26	2007-06-07	쿠도스 파마슈티칼스 리미티드	4-헤테로아릴메틸 치환된 프탈라지논 유도체
GB0419072D0 (en)	2004-08-26	2004-09-29	Kudos Pharm Ltd	Phthalazinone derivatives
US20090226412A1 (en)	2005-06-24	2009-09-10	Ono Pharmaceutical Co., Ltd.,	Agent for reduction of bleeding in cerebrovascular disorder
GB0521373D0 (en)	2005-10-20	2005-11-30	Kudos Pharm Ltd	Pthalazinone derivatives
US8466150B2 (en) *	2006-12-28	2013-06-18	Abbott Laboratories	Inhibitors of poly(ADP-ribose)polymerase
MX347085B (es)	2006-12-28	2017-04-06	Abbott Laboratories *	Inhibidores de la poli (adp-ribosa) polimerasa.
TW200900396A (en) *	2007-04-10	2009-01-01	Kudos Pharm Ltd	Phthalazinone derivatives

2008
- 2008-09-12 WO PCT/GB2008/003080 patent/WO2009034326A1/en not_active Ceased
- 2008-09-12 KR KR1020107007470A patent/KR20100059950A/ko not_active Withdrawn
- 2008-09-12 JP JP2010524565A patent/JP2010539149A/ja active Pending
- 2008-09-12 BR BRPI0816679 patent/BRPI0816679A2/pt not_active IP Right Cessation
- 2008-09-12 AU AU2008299721A patent/AU2008299721A1/en not_active Abandoned
- 2008-09-12 CA CA2699038A patent/CA2699038A1/en not_active Abandoned
- 2008-09-12 RU RU2010108008/04A patent/RU2010108008A/ru not_active Application Discontinuation
- 2008-09-12 US US12/209,400 patent/US7981890B2/en not_active Expired - Fee Related
- 2008-09-12 MX MX2010002749A patent/MX2010002749A/es active IP Right Grant
- 2008-09-12 CN CN200880106493A patent/CN101809017A/zh active Pending
- 2008-09-12 EP EP08806239A patent/EP2188278A1/en not_active Withdrawn

Also Published As

Publication number	Publication date
CN101809017A (zh)	2010-08-18
MX2010002749A (es)	2010-06-25
EP2188278A1 (en)	2010-05-26
US7981890B2 (en)	2011-07-19
JP2010539149A (ja)	2010-12-16
US20090186897A1 (en)	2009-07-23
RU2010108008A (ru)	2011-10-20
KR20100059950A (ko)	2010-06-04
WO2009034326A1 (en)	2009-03-19
AU2008299721A1 (en)	2009-03-19
CA2699038A1 (en)	2009-03-19

Publication	Publication Date	Title
BRPI0813707A2 (pt)	2014-12-30	Derivados de pirimidinil-piridazinona
BRPI0820112A2 (pt)	2015-05-05	Derivados de isoxazol-piridina
BRPI0809992A2 (pt)	2014-10-14	Derivados de pirrolopirimidina
BRPI0820113A2 (pt)	2015-05-05	Derivados de isoxazolo-piridazina
BRPI0815717A2 (pt)	2015-02-10	Compostos de imidazopirazina.
BRPI0813235A2 (pt)	2014-12-23	Combinação anti-helmíntica.
BRPI0811718A2 (pt)	2014-11-18	Derivados de 3,3-espiroindolinona
BRPI0812155A2 (pt)	2019-09-24	derivados de espiroindolinona
BRPI0817935A2 (pt)	2015-04-07	Derivados de biarila
FR2909857B1 (fr)	2009-03-06	Endovalve.
HRP20151058T1 (xx)	2015-12-04	Ariloazol-2-il-cijanoetilamino-spojevi, postupak njihove proizvodnje i postupak njihove uporabe
ATE513831T1 (de)	2011-07-15	Pyridinä3,4-büpyrazinone
ATE555107T1 (de)	2012-05-15	2-aza-bicyclo-ä2,2,1-üheptan-derivate
BRPI0814236A2 (pt)	2015-01-06	Derivados de quinazolinamida
BRPI0812518A2 (pt)	2015-03-31	Derivados de indazolamida
BRPI0820649A2 (pt)	2015-06-16	Derivados de isoxazalo-pirazina
BRPI0813836A2 (pt)	2015-01-06	Derivados pirazólicos
DE602008005634D1 (de)	2011-04-28	1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivate
BRPI0917446A2 (pt)	2015-12-22	derivados de acilaminobenzamida.
BRPI0906714A2 (pt)	2015-06-30	Derivados de oxazepinopirimidona heteroarilamida substituídos.
BRPI0814718A2 (pt)	2015-02-24	Derivados de isoxazol-imidazol
BRPI0811214A2 (pt)	2014-10-29	Derivados de pirazolona
ATE467626T1 (de)	2010-05-15	Indol-2-yl-piperazin-1-yl-methanon-derivate
BRPI0812827A2 (pt)	2014-12-09	Derivados de macrolactona
BRPI0812816A2 (pt)	2014-12-23	Derivados de sulfonil-quinolina

Legal Events

Date	Code	Title	Description
2015-12-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.
2016-04-05	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.